1. Home
  2. PRAA vs ANL Comparison

PRAA vs ANL Comparison

Compare PRAA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PRA Group Inc.

PRAA

PRA Group Inc.

HOLD

Current Price

$17.53

Market Cap

639.1M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.43

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAA
ANL
Founded
1996
2004
Country
United States
United States
Employees
170
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
639.1M
731.6M
IPO Year
2002
2022

Fundamental Metrics

Financial Performance
Metric
PRAA
ANL
Price
$17.53
$10.43
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$24.50
$20.00
AVG Volume (30 Days)
872.1K
108.2K
Earning Date
05-07-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.73
N/A
Revenue
$1,201,837,000.00
N/A
Revenue This Year
$2.01
$36.02
Revenue Next Year
$2.53
N/A
P/E Ratio
$21.73
N/A
Revenue Growth
7.83
N/A
52 Week Low
$10.25
$0.88
52 Week High
$22.55
$17.25

Technical Indicators

Market Signals
Indicator
PRAA
ANL
Relative Strength Index (RSI) 61.80 45.81
Support Level $16.60 $9.46
Resistance Level $17.78 $12.59
Average True Range (ATR) 0.91 1.14
MACD 0.32 0.03
Stochastic Oscillator 99.59 47.86

Price Performance

Historical Comparison
PRAA
ANL

About PRAA PRA Group Inc.

PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: